Phase I Study of Direct Coagulation Factor Xa Inhibitor SYHA136 Tablets in Chinese Healthy Volunteers

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
Links ClinicalTrials.gov
The trial used single‐center, randomized, double‐blind, placebo‐controlled, single‐dose ascending study. The trial planned to enroll fifty‐six healthy volunteers. The subjects were allocated to eight dose groups, including 0.5 mg (3+1), 1 mg (3+1), 2.5 mg (6+2), 5 mg (6+2), 10 mg (6+2), 20 mg (6+2), 35 mg(6+2) and 50 mg (6+2). Each dose group was allocated test drugs and placebos according to the proportion of subjects in the brackets mentioned above.
Epistemonikos ID: 792509c1c50e7e56339b702e117d4cdb15bb86b3
First added on: May 22, 2024